Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecan

Key Points

• Enhanced susceptibility to trastuzumab deruxtecan is linked to targeted inhibition of fbxl2, affecting treatment outcomes.
• The observed effect shows a significant increase in response rates for patients with her2-negative breast cancer.
• The analysis utilized computational models to assess molecular pathways influenced by fbxl2 inhibition in cancer cells.
• This highlights the need for further investigation into targeted therapies for improving treatment responses in breast cancer.